TY  - CONF
AU  - Öz, S.
AU  - Gao, Y.
AU  - Schmid, J.P.
AU  - Jeremias, I.
C1  - 74703
C2  - 57569
CY  - Oswald-hesse-strasse 50, D-70469 Stuttgart, Germany
SP  - 181 - 182
TI  - CCND3 Knockout Impairs Leukemia Growth in PDX AML Models Revealing a New Therapeutic Vulnerability.
JO  - Klin. Padiatr.
VL  - 237
IS  - 03
PB  - Georg Thieme Verlag Kg
PY  - 2025
SN  - 0300-8630
ER  - 

TY  - JOUR
AB  - BACKGROUND: Nitrogen multiple breath washout (N2MBW) is a lung function test increasingly used in small airway diseases. Quality criteria have not yet been globally implemented and time-consuming retrospective overreading is necessary. Little data has been published on children with recurrent wheeze or asthma from multicentered studies. METHODS: Children with wheeze or asthma and healthy controls were included in the longitudinal All Age Asthma Cohort (ALLIANCE). To assess ventilation inhomogeneity, N2MBW tests were performed in five centers from 2013 until 2020. All N2MBW tests were centrally overread by one center. Multiple washout procedures (trials) at the visit concluded to one test occasion. Tests were accepted if trials were technically sound (started correctly, terminated correctly, no leak, regular breathing pattern) and repeatable within one test occasion. Signal misalignment was retrospectively corrected. Factors that may impact test quality were analyzed, such as experience level. RESULTS: N2MBW tests of n=561 participants were analyzed leading to n=949 (68.3%) valid tests of n=1,390 in total. Inter-center test acceptability ranged from 27.6% to 77.8%. End-of-test criterion and leak were identified to be the most common reasons for rejection. Data loss and uncorrectable signal misalignment led to rejection of 58% of trials in one center. In preschool children, significant improvement of test acceptability was found longitudinally (χ2(8)=18.6; p=0.02). CONCLUSION: N2MBW is feasible in a multicenter asthma study in children. However, the quality of this time-consuming procedure is dependent on experience level of staff in preschool children and still requires retrospective overreading for all age groups.
AU  - Nitsche, C.*
AU  - Frauchiger, B.S.*
AU  - Thiele, D.*
AU  - Oestreich, M.A.*
AU  - Husstedt, B.L.*
AU  - Grychtol, R.M.*
AU  - Maison, N.
AU  - Foth, S.*
AU  - Meyer, M.*
AU  - Jakobs, N.*
AU  - Bahmer, T.*
AU  - Hansen, G.*
AU  - von Mutius, E.
AU  - Kopp, M.*
C1  - 67271
C2  - 54207
CY  - Rudigerstr 14, D-70469 Stuttgart, Germany
SP  - 66-74
TI  - Quality control of nitrogen multiple breath washout in a multicenter pediatric asthma study.
JO  - Klin. Padiatr.
VL  - 235
IS  - 2
PB  - Georg Thieme Verlag Kg
PY  - 2023
SN  - 0300-8630
ER  - 

TY  - CONF
AU  - Gao, Y.
AU  - Ghalandary, M.
AU  - Becker, M.
AU  - Amend, D.
AU  - Rothenberg-Thurley, M.*
AU  - Metzeler, K.H.*
AU  - Jeremias, I.
C1  - 65613
C2  - 52382
SP  - 185-185
TI  - Mutations in KRAS and DNMT3A are not related to dependency in established tumors, in PDX acute leukemia model in vivo.
JO  - Klin. Padiatr.
VL  - 234
IS  - 03
PY  - 2022
SN  - 0300-8630
ER  - 

TY  - CONF
AU  - Hunt, K.
AU  - Amend, D.
AU  - Ludwig, R.
AU  - Vick, B.
AU  - Wirth, A.-K.
AU  - Herold, T.
AU  - Jeremias, I.
C1  - 65611
C2  - 52381
SP  - 184-184
TI  - Streamlining preclinical in vivo treatment trials by multiplexing genetically labelled PDX models in a single mouse.
JO  - Klin. Padiatr.
VL  - 234
IS  - 03
PY  - 2022
SN  - 0300-8630
ER  - 

TY  - JOUR
AU  - Wachter, F.
AU  - Grunert, M.
AU  - Jeremias, I.
AU  - Ehrhardt, H.
C1  - 27997
C2  - 32894
SP  - 218
TI  - TRAIL targets cell cycle arrested tumor cells.
JO  - Klin. Padiatr.
VL  - 224
PB  - Thieme
PY  - 2012
SN  - 0300-8630
ER  - 

TY  - JOUR
AB  - We report the case of a 2-year-old boy with immune thrombocytopenia (ITP) who developed fatal intracranial hemorrhage (ICH) despite maximum therapy according to the guidelines. Hitherto defined risk factors do not predict severe or atypical courses.
AU  - Uetz, B.*
AU  - Wawer, A.*
AU  - Nathrath, M.
AU  - Burdach, S.
C1  - 6400
C2  - 28616
CY  - Stuttgart
SP  - 383-385
TI  - Intracranial hemorrhage in immune thrombocytopenia (ITP): Fatal course in spite of maximum therapy.
JO  - Klin. Padiatr.
VL  - 222
IS  - 6
PB  - Thieme
PY  - 2010
SN  - 0300-8630
ER  - 

TY  - JOUR
AB  - Inducible co-stimulator (ICOS) interaction with its ligand (ICOSL) is involved in several T cell effector functions. While blockade of ICOS:ICOSL interaction in chronic graft versus host disease (GVHD) seems beneficial, results for acute GVHD remain controversial. To further elucidate its role in acute GVHD, C57BL/6 mice were reconstituted with allogeneic spleen cells in the absence or presence of ICOSL-blocking mAb. Mice reconstituted with allogeneic spleen cells experienced severe GVHD and died untreated within 6-9 days after transplantation. Mice treated with an anti-ICOSL mAb starting from day 3 after transplantation gained weight again and survived for at least additional 12 days, although the treatment was already stopped at day 11 after transplantation. In contrast, the anti-ICOSL treatment starting from day 0 did not prevent GVHD. The difference between therapeutic (day 3) and prophylactic (day 0) anti-ICOSL treatment was independent of CD25+CD4+ regulatory T cells since their depletion did not abrogate the therapeutic effect of ICOSL blockade. Microarray analysis revealed IFN-gamma and chemokine up-regulation in spleen cells of prophylactically treated mice, emphasizing kinetic dependence of acute GVHD modulation via blockade of ICOS:ICOSL interaction.
AU  - Mollweide, A.*
AU  - Staege, M.S.*
AU  - Hoeschen, C.
AU  - Hideo, Y.*
AU  - Burdach, S.*
AU  - Richter, G.H.
C1  - 3850
C2  - 28551
CY  - Stuttgart
SP  - 344-350
TI  - Only therapeutic ICOS:ICOSL blockade alleviates acute graft versus host disease.
JO  - Klin. Padiatr.
VL  - 221
IS  - 6
PB  - Thieme
PY  - 2009
SN  - 0300-8630
ER  - 

TY  - JOUR
AB  - Background: The prognosis of patients with osteosarcoma has considerably improved over the last 30 years, mainly due to developments in chemotherapy. However, almost half of the osteosarcomas do not respond to chemotherapy. Predictive markers for chemosensitivity at diagnosis are desirable. Patients and Methods: In order to investigate the potential of some chemotherapy-associated genes with respect to their predictive value for chemosensitivity, the mRNA expression of 8 genes was evaluated in the osteosarcomas of 45 patients and correlated to the histological response to neoadjuvant chemotherapy. Results: ERCC4, a member of the nucleotide excision repair system, showed a orrelation between expression and the histologically evaluated response to chemotherapy. The expression of the other investigated genes HER-2/neu, HSP 70, GST, DHFR, BCRP, ERCC1 and Mlh1 showed no significant correlation to response to chemotherapy. Conclusion: In our retrospective analyses, low expression of ERCC4 was shown to be related to poor response to chemotherapy. The potential value of ERCC4 as response predictor has to be investigated in a prospective study.
AU  - Nathrath, M.
AU  - Kremer, M.*
AU  - Letzel, H.*
AU  - Remberger, K.*
AU  - Höfler, H.
AU  - Ulle, T.
C1  - 10016
C2  - 20447
SP  - 230-235
TI  - Expression von Genen mit möglicher prognostischer Bedeutung für das Ansprechen auf Chemotherapie bei Patienten mit Osteosarkom : Gene mit möglicher prognostischer Bedeutung beim Osteosarkom. 
JO  - Klin. Padiatr.
VL  - 214
PB  - Thieme
PY  - 2002
SN  - 0300-8630
ER  - 

TY  - JOUR
AU  - Roskrow, M.A.
AU  - Zibert, A.*
AU  - Souquet, M.*
AU  - Dilloo, D.*
C1  - 21068
C2  - 19098
SP  - 336-346
TI  - Tumor vaccines: Application to childhood cancer.
JO  - Klin. Padiatr.
VL  - 211
PY  - 1999
SN  - 0300-8630
ER  - 

TY  - JOUR
AB  - Periphere Blasten von 4 Patienten mit einer akuten lymphoblastischen Leukämie (ALL) vom common Typ und Zellen der permanenten leukämischen Linie Reh wurden in Diffusionskammern (DC) gefüllt und in lethal bestrahlten CBA-Mäusen (8 gy) kultiviert. Zur immunologischen Charakterisierung wurden die Zellen mit heterologen Antiseren markiert. Die Auswertung erfolgte durch Einsatz der direkten Immunfluoreszenz. Zusätzlich wurde in einzelnen Fällen die Anzahl von Zellen, die mit Schafs- oder Mäuseerythrozyten Rosetten bildeten, bestimmt. In allen Fällen kam es während der Kulturperiode zu deutlichen Veränderungen der Oberflächenmerkmale, die für eine Entwicklung in die B- oder T-Zellreihe sprachen. Gemessen an der Vielfalt von Membranmarkern erreichte die Ausreifung unterschiedliche Grade und erstreckte sich innerhalb des B-Zellzweiges vom Rezeptor für Mäuse-erythrozyten bis zur Expression von membrangebundenem Immunglobulin. Im Falle der Zeil-Linie führte der Differenzierungsprozeß sowohl zum Auftreten von Zellen mit Charakteristika von immunkompetenten T-Lymphozyten als auch unreifen B-Lymphozyten. Diesen Ergebnissen nach zu urteilen, verhalten sich leukämische ALL-Blasten vom common-Typ unter den Bedingungen der DC-Kultur wie Vorläuferzellen des lymphatischen Systems.
AU  - Lau, B.
AU  - Jäger, G.
AU  - Pachmann, K.
AU  - Thiel, E.V.*
AU  - Dörmér, P.G.*
C1  - 42314
C2  - 40386
SP  - 147-151
TI  - Membrandifferenzierung von Zellen aktuter Lymphoblastischer Leukamien vom cAll-TYP  in Diffusionskammern.
JO  - Klin. Padiatr.
VL  - 195
IS  - 3
PY  - 1983
SN  - 0300-8630
ER  - 

TY  - JOUR
AB  - The experimental background, methods of preventing immunological complications and clinical results of bone marrow transplantation in cases with aplastic anemia and acute leukemia in relapse are reported. The causes for failures in clinical bone marrow transplantations are discussed. The possibilities of bone marrow transplantation appear superior to conventional therapeutic measures, if a histocompatible sibling donor is available.
AU  - Kolb, H.J.
C1  - 41531
C2  - 40414
SP  - 60-67
TI  - Knochenmarktransplantation bie Knochenmarkaplasie und Akuter Leukämie - Voraussetzungen, Erfolge, Indikationen.
JO  - Klin. Padiatr.
VL  - 189
IS  - 1
PY  - 1977
SN  - 0300-8630
ER  -